Therapeutic anti-cytomegalovirus compounds

Details Therapeutic anti-cytomegalovirus compounds Therapeutic anti-cytomegalovirus compounds

2007-02-16

2011-10-04

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S230100, C530S328000, C514S021600

Reexamination Certificate

active

08029796

ABSTRACT:
The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.

REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4754065 (1988-06-01), Levenson et al.
patent: 4800159 (1989-01-01), Mullis et al.
patent: 5440013 (1995-08-01), Kahn
patent: 5837249 (1998-11-01), Heber-Katz et al.
patent: 0702 082 (1996-03-01), None
patent: 2 757 169 (1998-06-01), None
patent: WO 96/23060 (1996-08-01), None
patent: WO98/21233 (1998-05-01), None
patent: WO 99/02183 (1999-01-01), None
patent: WO 99/36568 (1999-07-01), None
Parker et al (Journal of Immunology 149:3580-3587, 1992).
Slansky et al (Immunity 13:529-538, 2000).
Gavin et al (European Journal of Immunology 24:2124-2133, 1994).
Altman, J.D. et al., “Phenotypic analysis of antigen-specific T lymphocytes” (1996)Science 274(5284):94-96.
Bertoni, R. et al., “Human class I supertypes and CTL repertoires extend to chimpanzees” (1998)J. Immunol. 161:4447-55.
Boczkowski, D. et al., “Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo” (1996)J. Exp. Med. 184:465-72.
Bordignon, C. et al., “Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells” (1989)Proc. Natl. Acad. Sci. USA 86:6748-52.
Carter, B.J., “Adeno-associated virus vectors” (1992)Curr. Op. Biotechnol. 3:533-39.
Caruso, A. et al., “Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation” (1997)Cytometry 27:71-76.
Correll, P.H. et al., “Production of human glucocerebrosidase in mice after retroviral gene transfer into multipotential hematopoietic progenitor cells” (1989)Proc. Natl. Acad. Sci. USA 86:8912-16.
Coulie, P.G., “Human tumor antigens recognized by T cells: new perspectives for anti-cancer vaccines?” (1997)Molec. Med. Today 3:261-68.
Culver, K., et al., “Lymphocytes as cellular vehicles for gene therapy in mouse and man” (1991)Proc. Natl. Acad. Sci. USA 88:3155-59.
Dharanipragada, R. et al., “The absolute configuration of an intermediate in the asymmetric synthesis of unusual amino acids” (1992)Acta. Cryst. C48:1239-41.
Dharanipragada, R. et al., “Synthetic linear and cyclic glucagon antagonists” (1993)Int. J. Peptide Protein Res. 42(1):68-77.
DiMaio, J. et al., “Synthesis of chiral piperazin-2-ones as model peptidomimetics” (1989)J. Chem. Soc. Perkin Trans. 1(9):1687-89.
Feltkamp, M.C.W. et al., “Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization” (1995)Immunol. Lett. 47:1-8.
Ferguson, et al. “Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures” (1988)Ann. Rev. Biochem. 57:285-320.
Fujihashi, K. et al., “Cytokine-specific ELISPOT assay single cell analysis of IL-2, IL-4 and IL-6 producing cells” (1993)J. Immunol. Meth. 160:181-89.
Garvey D.S. et al., “3,4-disubstituted γ-lactam rings as conformationally constrained mimics of peptide derivatives containing aspartic acid or norleucine” (1990)J. Org. Chem. 55(3):936-40.
Hruby, V.J., “Conformational restrictions of biologically active peptides via amino acid side chain groups” (1982)Life Sciences 31:189-99.
Hruby, V.J. et al., “Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations” (1990)Biochem J. 268:249-62.
Isakov, N. et al., “ZAP-70 binding specificity to T cell receptor tyrosine-based activation motifs: The tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity” (1995)J. Exp. Med. 181:375-80.
Jones, R.C.F. and G. J. Ward, “Amide bond isosteres: imidazolines in pseudopeptide chemistry” (1988)Tetrahedron Lett., 29(31)3853-56.
Kahn, M. and S. Bertenshaw, “The incorporation of β-turn prosthetic units into Merrifield solid phase peptide synthesis” (1989)Tetrahedron Lett. 30(18):2317-20.
Karlsson, S. et al., “Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors” (1986)EMBO J. 5(9):2377-85.
Kawakami, Y. et al., “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor” (1994)Proc. Natl Acad. Sci. USA 91(9):3515-19.
Kazmierski, W.M. and V. J. Hruby, “Asymmetric synthesis of topographically constrained amino acids: synthesis of the optically pure isomers of α,β-dimethyl-phenylalanine and α,β-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid” (1991)Tetrahedron Lett. 32(41):5769-72.
Kazmierski, W.M. et al., “Topographic design of peptide neurotransmitters and hormones on stable backbone templates: relation of conformation and dynamics to bioactivity” (1991)J. Am. Chem. Soc. 113:2275-83.
Kemp, D.S. and P.E. McNamara, “Conformationally restricted cyclic nonapeptides derived from L-cysteine and LL-3-amino-2-piperidone-6-carboxylic acid (LL-Acp), A potent β-turn-inducing dipeptide analogue” (1985)J. Org. Chem. 50:5834-38.
Kemp, D.S. and B.R. Bowen, “Conformational analysis of peptide-functionalized diacylaminoepindolidiones1H NMR evidence for β-sheet formation” (1988)Tetrahedron Lett. 29(40):5081-82.
Kemp, D.S. and W.E. Stites, “A convenient preparation of derivatives of 3(S)-amino-10(R)-carboxy-1,6-diaza-cyclodeca-2,7-dione; The dilactam of L-α,γ-diaminobutyric acid and D-glutamic acid: A β-turn template” (1988)Tetrahedron Lett. 29(40):5057-60.
Kemp, D.S. and T.P. Curran, “(2,5S, 8S, 11S)-1-acetyl-1,4-diaza-3-keto-5-carboxy-10-thia-tricyclo-[2.8.04,8]-ridecane, 1 the preferred conformation of 1 (1=αtemp-OH) and its peptide conjugates αtemp-L-(Ala)a-OR(n=1 to 4) and α-temp-L-Ala-L-Phe-Lys(ε-Boc)-NHMe studies of templates for α-helix formation” (1988)Tetrahedron Lett. 29(39):4935-38.
Kemp, D.S. and J.S. Carter, “Amino acid derivatives that stabilize secondary structures of polypeptides. 4. Practical synthesis of 4-(alkylamino)-3-cyano-6-azabicyclo[3.2.1]oct-3-enes (ben derivatives) as γ-turn templates” (1989)J. Org. Chem. 54:109-115.
McLaughin-Taylor, et al., “Identification of the Major Late Human Cytomegalovirus Matrix Protein pp65 as a Target Antigen for CD8+ Virus-Specific Cytotoxic T Lymphocytes” (1994)J. Medical Virology, 43:103-110.
McGrory, W.J. et al., “Short communications: A simple technique for the rescue of early region 1 mutation into infectious human adenovirus type 5” (1988)Virology 163:614-17.
Merrifield, R.B., “New approaches to the chemical synthesis of peptides” (1967)Recent Progress in Hormone Res. 23:451-482.
Miyake, A. et al., “Synthesis and angiotensin converting enzyme inhibitory activity of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives” (1984)J. Takeda Res. Labs. 43(3/4):53-76.
Mosier, D.E. et al., “Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160” (1993)Proc. Natl. Acad. Sci. USA 90:2443-47.
Muzcyzka, “Use of adeno-associated virus as a general transduction vector for mammalian cells” (1992) Curr. Top.Microbiol. Immunol

Affiliated with

Also associated with

Rating

Therapeutic anti-cytomegalovirus compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic anti-cytomegalovirus compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic anti-cytomegalovirus compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4262310